Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Novavax, Inc.

Market Cap 1.5B 1.31B 1.21B 1.13B 2.13B 142B 2.14B 14.38B 5.57B 69.73B 5.64B 5.51B 242B P/E 2026 *
-19.3x
P/E 2027 * -35.9x
Enterprise Value 1.72B 1.5B 1.39B 1.3B 2.44B 162B 2.45B 16.48B 6.39B 79.9B 6.46B 6.32B 277B EV / Sales 2026 *
4.2x
EV / Sales 2027 * 6.98x
Free-Float
93.1%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 2023-01-22
Director of Finance/CFO 60 2021-08-15
Chief Operating Officer - 2020-11-30
Director TitleAgeSince
Director/Board Member 73 2010-08-05
Director/Board Member 66 2018-10-31
Director/Board Member 60 2020-06-15
Change 5-day change 1-year change 3-year change Capi.($)
-12.33%+1,148.37% - - 1.5B
+1.44%+1.71%-10.98%-5.59% 43.13B
+3.31%+5.93%+310.97%+532.23% 34.65B
+2.84%+2.14%+9.34%+45.55% 30.03B
-1.70%-7.54%+8.43%-21.54% 28B
-1.90%-1.56%+10.24%+22.81% 24.45B
-0.14%+5.86% - - 14.34B
+0.68%-1.53%+48.76%+108.76% 13.14B
-0.57%-2.43%+5.08%+6.76% 12.53B
-0.26%+1.15%+98.13%+79.60% 12.25B
Average -0.86%+0.73%+60.00%+96.07% 23.61B
Weighted average by Cap. +0.68%+1.27%+65.47%+111.07%

Financials

2026 *2027 *
Net sales 410M 357M 331M 310M 581M 38.68B 585M 3.93B 1.52B 19.04B 1.54B 1.51B 66.12B 258M 225M 209M 195M 366M 24.39B 369M 2.48B 960M 12B 970M 949M 41.68B
Net income -79.31M -69.15M -64.04M -59.95M -112M -7.48B -113M -760M -294M -3.68B -298M -291M -12.79B -43.22M -37.69M -34.9M -32.67M -61.28M -4.08B -61.65M -414M -160M -2.01B -162M -159M -6.97B
Net Debt 219M 191M 177M 166M 310M 20.66B 312M 2.1B 813M 10.17B 822M 804M 35.32B 303M 264M 245M 229M 430M 28.61B 432M 2.9B 1.13B 14.08B 1.14B 1.11B 48.9B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!